Safety and Efficacy Study of CVD 1208S, a Live, Attenuated Oral Vaccine to Prevent Shigella Infection Using cGMP

Phase 1 Completed 26 enrolled University of Maryland, Baltimore PATH · collab

RandomizedParallel-groupQuadruple-blindPrevention

Summary

The purpose of this study is to determine whether CVD 1208S (a live, attenuated, oral vaccine) is safe and effective in the prevention of Shigella infection.

Timeline

Start: 2011-07
Primary completion: 2012-09
Completion: 2012-09

Publications

Toapanta FR, Bernal PJ, Kotloff KL, Levine MM, Sztein MB. T cell mediated immunity induced by the live-attenuated Shigella flexneri 2a vaccine candidate CVD 1208S in humans. J Transl Med. 2018 Mar 13;16(1):61. doi: 10.1186/s12967-018-1439-1.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	CVD 1208S	Vaccine	108 unknown	Oral

Safety and Efficacy Study of CVD 1208S, a Live, Attenuated Oral Vaccine to Prevent Shigella Infection Using cGMP

Summary

Timeline

Publications

Drugs

Indications